Сonfirmatory study of the efficacy and tolerability of trifluridine/tipiracil (TAS-102) therapy in the Russian population with chemorefractory metastatic colorectal cancer

Introduction. Trifluridine/Tipiracil (FTD/TPI) is a new chemotherapeutic drug approved in more than 60 countries for use in patients with metastatic colorectal cancer who have registered progression or intolerance to treatment with fluoropyrimidines, oxaliplatin and irinotecan, anti-VEGRand anti-EGFR-targeted agents. This study evaluated for the first time the effectiveness and tolerability of FTD/TPI therapy in the Russian patient population.

Materials and methods. A confirmatory open-label single-arm non-randomized trial was conducted in 2 clinical centres in Russia. The main criteria for inclusion were: conduction of at least the 2nd line of standard systemic therapy for metastatic colon adenocarcinoma. The primary efficacy criteria were: 2-month progression-free survival; secondary – median progressionfree survival, disease control frequency, safety assessment, overall survival. Research number: NCT03274882.

Results. A total of 26 patients were included in the study; the median age was 60.5 years (30 to 78); 19 (73%) women; and 4 patients with ECOG 0 and 22 – with ECOG 1. All patients were previously treated with the inclusion of oxaliplatin, irinotecan, fluoropyrimidines, 21 (81%) – bevacizumab, 6 (23%) – anti-EGFR antibodies, and 2 (7.7%) – regorafenib. The median for treatment courses was 4 (1–21), 11 (42.3%) patients were treated for 6 months or more. The two-month progression-free survival rate was 52% with a median progreesion-free survival rate of 4 months (95% CI 1.8–7.4 months). The median of total survival rate was 11 months (95% CI 5,2–16,8 months). Disease control was achieved in 60%. Neutropenia, nausea, vomiting, anemia, weakness prevailed among undesirable events associated with treatment (≥5 patients). The majority of complications were of the 1st–2nd degree. Among the undesirable events of the 3rd–4th degree, neutropenia was more common, while in 3 patients febrile neutropenia of the 3rd degree was registered.

Conclusions. In the Russian population of patients with colorectal chemorefractory cancer, the drug FTD/TPI (TAS-102) shows efficacy and tolerability comparable to the RECOURSE registration study.

1. Kish T., Uppal P. Trifluridine/Tipiracil (Lonsurf) for the treatment of metastatic colorectal Cancer. PT. 2016;41(5):314–325. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4849340/

2. Mayer R.J., Ohtsu A., Yoshino T., Falcone A., Garcia-Carbonero R., Tabernero J. et al. TAS-102 versus placebo plus best supportive care in patients with metastatic colorectal cancer refractory to standard therapies: final survival results of the phase III recourse trial. J Clin Oncol. 2016;34(4S):634. doi: 10.1200/jco.2016.34.4_suppl.634.

3. Van Cutsem E., Mayer R.J., Laurent S., Winkler R., Grávalos C., Benavides M. et al. The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer. Eur J Cancer. 2018;90:63–72. doi: 10.1016/j.ejca.2017.10.009.

4. Johnson N.L., Kotz S., Kemp A.W. Univariate discrete distributions. 2th ed. John Wiley & Sons; 1992. 565 p. Available at: https://ideas.repec.org/a/eee/csdana/v17y1994i2p240-241.html.

5. Mayer R.J., Van Cutsem E., Falcone A., Yoshino T., Garcia-Carbonero R., Mizunuma N. et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372(20):1909–1919. doi: 10.1056/NEJMoa1414325.

6. Cremolini C., Rossini D., Martinelli E., Pietrantonio F., Lonardi S., Noventa S. et al. Trifluridine/Tipiracil (TAS-102) in refractory metastatic colorectal cancer: a multicenter register in the frame of the Italian compassionate use program. Oncologist. 2018;23(10):1178–1187. doi: 10.1634/theoncologist.2017-0573.

7. Garcia-Carbonero R., Van Cutsem E., Ciardiello F., Sobrero A., Banzi C., Barone C. et al. Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the phase 3b CONSIGN trial who had progression-free survival (PFS) >4 months (m). Ann Oncol. 2016;27(4 Suppl.):39–54. doi: 10.1093/annonc/mdw335.27.

8. Grothey A., Falcone A., Humblet Y., Bouche O., Mineur L., Adenis A. et al. Characteristics of patients (pts) with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) who had progression-free survival (PFS) >4 months (m): Subgroup analysis of the phase 3 CORRECT trial. Ann Oncol. 2016;27(6 Suppl.):149–206. doi: 10.1093/annonc/mdw370.64.

9. Masuishi T., Taniguchi H., Kawakami T., Kawamoto Y., Kadowaki S., Onozawa Y. et al. Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer. ESMO Open. 2019;4(6):e000584. 2016;27(6):506. doi: 10.1136/esmoopen-2019-000584.

10. Fernandez Montes F.A., Vazquez Rivera F., Martinez Lago M., Covela Rúa M., Cousillas Castiñeiras A., Gonzalez Villarroel P. et al. Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram. Clin Transl Oncol. 2020;22(3):351–359. 2016;27(6):506. doi: 10.1007/s12094-019-02130-x.

11. Kotani D., Kuboki Y., Horasawa S., Kaneko A., Nakamura Y., Kawazoe A. et al. Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer. BMC Cancer. 2019;19(1):1253. doi: 10.1186/s12885-019-6475-6.

12. Pfeiffer P., Yilmaz M., Möller S., Zitnjak D., Krogh M., Petersen L.N. et al. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21(3):412–420. 2016;27(6):506. doi: 10.1016/S1470-2045(19)30827-7.